Abstract 718: Microrna-29A* is a Predictor for Early Recurrence Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection

Hai-Tao Zhu,Qiong-Zhu Dong,Yuan-Yuan Sheng,Jin-Wang Wei,Guan Wang,Hai-Jun Zhou,Ning Ren,Hu-Liang Jia,Qing-Hai Ye,Lun-Xiu Qin
DOI: https://doi.org/10.1158/1538-7445.am2012-718
IF: 11.2
2012-01-01
Cancer Research
Abstract:Abstract Purpose: Early tumor recurrence after liver resection for hepatocellular carcinoma (HCC) was mainly due to intrahepatic tumor spreading. In this study, we set out to identify specific microRNA (miRNA) which might be used in predicting the possibility of early recurrence after HCC resection. Experimental Design: Taqman low density arrays were used to detect the miRNA expression levels in both the microdissected tumorous and adjacent non-tumorous liver tissues from 20 HCC patients. Quantitative real-time PCR (qRT-PCR) was used to verify the findings in 106 patients, and to develop a predictive assay. The identified miRNAs were further validated in an independent cohort of 112 patients. Results: Thirty seven selected miRNAs were validated in 106 HCC patients using qRT-PCR. A significant association was found between miR-29a* level in HCC tissues and early recurrence (P=0.0002). This association was further confirmed in the independent testing set of 112 patients (P=0.0154), in which miR-29a* level was significantly associated with both time to tumor recurrence (TTR) (P=0.0015) and overall survival (OS) (P=0.0079) of patients. In the univariate and multivariate analyses, miR-29a* was identified as an independent factor for TTR, particularly for those patients with early stage of HCC. The sensitivity and specificity of miR-29a* for the prediction of early HCC recurrence in an independent blinded validation set reached 74.2% and 68.2%, respectively. Conclusion: MiR-29a* might be a useful marker for prediction of early recurrence of HCC, particularly for those with early stage of HCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 718. doi:1538-7445.AM2012-718
What problem does this paper attempt to address?